Case Studies for Value Added Medicines. Unlocking the potential of patient-centric continuous innovation

26 February 2019

Policy, Report

Joint pharmaceutical industry statement on the Commission’s proposal for a Regulation on health technology assessment (HTA)

21 June 2018

Policy

Position paper on Best Procurement Practices

28 April 2018

Policy

Fighting counterfeit medicines in Europe: the effect on access to medicines

14 September 2017

Policy

The implementation of the Falsified Medicines Directive, and its Delegated […]

ISPOR 2016 EU – Value Added Medicines

18 November 2016

Policy, Report

Healthcare System Inefficiencies Related To Medicines: Any Potential Room For […]

Essential Medicines for Universal Health Coverage

7 November 2016

Policy

Value Added Medicines: Rethink, Reinvent & Optimize Medicines, Improving Patient Health & Access

31 May 2016

Policy, Report

Launch of European Value Added medicines (EVA), a new EGA sector group, will deliver efficiency

12 June 2015

Policy

Brussels – The European Generic and Biosimilar medicines Association (EGA) announced […]